Your competitor isn’t “innovating.” They’re extending. Here are 4 signals to watch.
In pharma, the most expensive word in the room is often the quietest: extension.
A competitor doesn’t always need a breakthrough to protect revenue. Sometimes they just…
Read the Patent Trail: 4 Signals Your Competitor Is Extending a Drug’s Life Read Post »
Biopharma teams don’t lose deals because they lack ambition. They lose because they’re late.
In licensing, partnering, and BD strategy, timing is everything—especially when the “product” isn’t just a molecule, but the entire go-to-market package around…
OpenAI’s “GPT for life sciences” is getting a lot of hype. But the real question for drug developers isn’t whether the model can sound smart—it’s whether it can change the economics of discovery.
That’s the tension at the heart of the latest discussion…
GPT-Rosalind: What OpenAI’s Life Sciences Model Actually Does to Drug Development Read Post »
Patent expiry intelligence isn’t just for forecasting—it’s for winning.
Most biosimilar teams treat patent expiry like a calendar event: identify the likely “go/no-go” window, model timelines, and then wait for the market to open. That approach is un…
Europe’s drug patent clock is ticking—here’s where it actually runs out (and why it matters now).
If you’re investing in pharma, building a pipeline, or advising on market entry, you’ve probably heard the headline version of European drug protection: “…
European Drug Patents: Exactly How Long Protection Lasts — and Where It Breaks Down Read Post »
Drug discovery is stuck in traffic—and the clock is the loudest honk in the room.
From target identification to lead optimization, the timeline is long, expensive, and increasingly unforgiving. Every delay compounds: data arrives late, experiments repe…
Slash drug discovery timelines with GPT-Rosalind Read Post »
The “Patent Expiration Cliff” Isn’t a Cliff—It’s a Window. Here’s How Commercial Market Access Teams Can Monetize It.
If you work in commercial market access, you’ve felt it: the sudden scramble when a blockbuster’s exclusivity timeline starts to tight…
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage in pharma isn’t just about winning the patent dance—it’s about what happens after the win.
Authorized generics (AGs) sit at the center of that real…
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits Read Post »
The clock is ticking—and “true generic” timing can make or break value.
In generic drugs, everyone talks about exclusivity. Fewer people talk about timing mechanics—the exact moment a product can legally enter, and how regulatory exclusivities interact…
Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…
Get new actionable insights and updates from BiotechBlog
